- Home
- MIST vs CGTX Comparison
MIST vs CGTX Comparison
Compare MIST & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- CGTX
- Stock Information
- Founded
- MIST 2003
- CGTX 2007
- Country
- MIST Canada
- CGTX United States
- Employees
- MIST N/A
- CGTX N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- MIST Health Care
- CGTX Health Care
- Exchange
- MIST Nasdaq
- CGTX Nasdaq
- Market Cap
- MIST 81.5M
- CGTX 79.3M
- IPO Year
- MIST N/A
- CGTX 2021
- Fundamental
- Price
- MIST $1.43
- CGTX $0.55
- Analyst Decision
- MIST Strong Buy
- CGTX Buy
- Analyst Count
- MIST 3
- CGTX 6
- Target Price
- MIST $13.00
- CGTX $8.00
- AVG Volume (30 Days)
- MIST 177.8K
- CGTX 588.8K
- Earning Date
- MIST 11-11-2024
- CGTX 11-08-2024
- Dividend Yield
- MIST N/A
- CGTX N/A
- EPS Growth
- MIST N/A
- CGTX N/A
- EPS
- MIST N/A
- CGTX N/A
- Revenue
- MIST N/A
- CGTX N/A
- Revenue This Year
- MIST N/A
- CGTX N/A
- Revenue Next Year
- MIST N/A
- CGTX N/A
- P/E Ratio
- MIST N/A
- CGTX N/A
- Revenue Growth
- MIST N/A
- CGTX N/A
- 52 Week Low
- MIST $1.12
- CGTX $0.34
- 52 Week High
- MIST $3.52
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- MIST 42.50
- CGTX 54.28
- Support Level
- MIST $1.41
- CGTX $0.50
- Resistance Level
- MIST $1.53
- CGTX $0.64
- Average True Range (ATR)
- MIST 0.07
- CGTX 0.07
- MACD
- MIST -0.01
- CGTX 0.02
- Stochastic Oscillator
- MIST 26.96
- CGTX 67.74
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.